- Home
- SWK vs BMRN Comparison
SWK vs BMRN Comparison
Compare SWK & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SWK
- BMRN
- Stock Information
- Founded
- SWK 1843
- BMRN 1996
- Country
- SWK United States
- BMRN United States
- Employees
- SWK N/A
- BMRN N/A
- Industry
- SWK Industrial Machinery/Components
- BMRN Biotechnology: Pharmaceutical Preparations
- Sector
- SWK Consumer Discretionary
- BMRN Health Care
- Exchange
- SWK Nasdaq
- BMRN Nasdaq
- Market Cap
- SWK 11.1B
- BMRN 12.1B
- IPO Year
- SWK N/A
- BMRN 1999
- Fundamental
- Price
- SWK $72.68
- BMRN $59.76
- Analyst Decision
- SWK Buy
- BMRN Buy
- Analyst Count
- SWK 10
- BMRN 23
- Target Price
- SWK $92.89
- BMRN $93.73
- AVG Volume (30 Days)
- SWK 2.0M
- BMRN 1.8M
- Earning Date
- SWK 07-29-2025
- BMRN 08-04-2025
- Dividend Yield
- SWK 4.43%
- BMRN N/A
- EPS Growth
- SWK N/A
- BMRN 152.82
- EPS
- SWK 2.41
- BMRN 2.71
- Revenue
- SWK $15,240,800,000.00
- BMRN $2,950,227,000.00
- Revenue This Year
- SWK $2.49
- BMRN $12.27
- Revenue Next Year
- SWK $4.19
- BMRN $9.99
- P/E Ratio
- SWK $30.72
- BMRN $22.09
- Revenue Growth
- SWK N/A
- BMRN 19.36
- 52 Week Low
- SWK $53.91
- BMRN $52.93
- 52 Week High
- SWK $110.88
- BMRN $94.85
- Technical
- Relative Strength Index (RSI)
- SWK 58.01
- BMRN 59.60
- Support Level
- SWK $69.42
- BMRN $56.48
- Resistance Level
- SWK $75.00
- BMRN $60.43
- Average True Range (ATR)
- SWK 2.03
- BMRN 1.52
- MACD
- SWK 0.08
- BMRN 0.27
- Stochastic Oscillator
- SWK 63.12
- BMRN 83.04
About SWK Stanley Black & Decker Inc.
Stanley Black & Decker Inc is a manufacturer of hand and power tools. The company operates in two reportable segments namely Tools and Outdoor and Industrial. It generates maximum revenue from the Tools and Outdoor segment. The Tools and Outdoor segment is comprised of the Power Tools Group (PTG), Hand Tools, Accessories and Storage (HTAS), and Outdoor Power Equipment (Outdoor) businesses. Geographically, the company generates revenue from the United States, Canada, Other Americas, Europe, and Asia. It derives a majority of its revenue from the United States.
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.